Core Viewpoint - The company plans to issue up to 37.8254 million shares at a price of HKD 6.53 per share, representing a discount of approximately 19.88% from the closing price of HKD 8.15 on September 29, 2025 [1] Summary by Categories Share Placement - The proposed share placement will account for about 7.03% of the total issued shares after the placement [1] - If all shares are successfully placed, the total proceeds from the placement are estimated to be approximately HKD 247 million, with net proceeds expected to be around HKD 245.8 million [1] Use of Proceeds - The net proceeds will be allocated as follows: - HKD 98 million for global channel development and brand system construction [1] - HKD 98 million for technology upgrades and supply chain security system development [1] - HKD 49.8 million for global headquarters construction, global management team formation, and other general operating expenses [1]

假设所有配售股份获悉数配售，净筹约5000万港元，拟用于清偿集团负债及用作集团一般营运资金。 小鱼盈通(00139)公布，于2025年9月26日，该公司拟透过配售代理向不少于六名承配人配售最多约2.05 亿股配售股份，配售价为每股配售股份0.25港元，较2025年9月26日在联交所所报收市价每股0.280港元 折让约11%。 ...

假设所有配售股份获悉数配售，净筹约5000万港元，拟用于清偿集团负债及用作集团一般营运资金。 智通财经APP讯，小鱼盈通(00139)公布，于2025年9月26日，该公司拟透过配售代理向不少于六名承配 人配售最多约2.05亿股配售股份，配售价为每股配售股份0.25港元，较2025年9月26日在联交所所报收市 价每股0.280港元折让约11%。 ...

Group 1 - The company, Sanofi Pharmaceutical-B (02257.HK), announced a subscription agreement to issue 17.3524 million shares at a subscription price of HKD 12.00 per share [1] - The total shares to be issued represent approximately 16.50% of the company's existing issued share capital and about 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price of HKD 12.00 per share reflects a discount of approximately 19.84% compared to the closing price of HKD 14.97 on September 5, the last trading day before the agreement [1] Group 2 - The total proceeds from the subscription are expected to be approximately HKD 208.2 million, with net proceeds around HKD 206 million [1] - The company plans to use the proceeds from the subscription for general working capital [1] - The subscribers include Huaxi Biotechnology (Hong Kong) Co., Ltd., Mr. Xie Shuohao, Bamboo Bloom Limited, and Capstone Resources Holding Limited [1]

Core Viewpoint - WuXi AppTec (02268) has entered into a placement agreement to issue up to 22.277 million shares at a price of HKD 58.85 per share, potentially raising approximately HKD 1.311 billion in total proceeds [1] Group 1: Placement Details - The placement is conditional and will be conducted through a placement agent to at least six independent third-party investors [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1.301 billion [1] Group 2: Use of Proceeds - Approximately 90% of the proceeds will be allocated to expanding the company's service capabilities and production capacity, including clinical and commercial production of antibody-drug conjugates and active pharmaceutical ingredients [1] - The remaining 10% will be used for working capital needs and general corporate purposes [1]

Group 1 - The company PACIFIC LEGEND (08547) plans to issue up to 82,107,900 shares at a price of HKD 0.468 per share, representing a premium of approximately 6.36% over the closing price of HKD 0.440 on the same day [1] - The maximum net proceeds from this placement are expected to be around HKD 38 million, which will be used for the company's working capital [1]

Group 1 - The company plans to issue 28.904 million new shares, representing approximately 8.3% of the enlarged share capital [1] - The subscription price is set at HKD 8.4 per share, which is a discount of 12.04% compared to the closing price of HKD 9.55 yesterday [1] - The total fundraising amount is expected to be HKD 243 million [1] Group 2 - Approximately 45% of the net proceeds from the placement will be allocated to preclinical research and clinical trials for localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - About 10% of the proceeds will be utilized for working capital and other general corporate purposes [1]

Core Viewpoint - Jingtai Holdings (02228) announced a placement agreement to issue up to approximately 286 million placement shares at HKD 9.28 per share, aiming to raise approximately HKD 2.63 billion for various strategic initiatives [1] Group 1: Fundraising Details - The company plans to issue up to approximately 286 million shares through a placement agent [1] - Each placement share is priced at HKD 9.28, with total net proceeds expected to be around HKD 2.63 billion if fully subscribed [1] Group 2: Use of Proceeds - The raised funds will be utilized for continuous product iteration and upgrading, enhancing research and development capabilities, and solution capabilities [1] - The company aims to commercialize products and develop business by strengthening collaborations with external parties in similar and mutually beneficial industries [1] - Additional uses include potential acquisitions and investments, talent attraction and recruitment, working capital replenishment, and general corporate purposes [1]

Core Viewpoint - Crystal Tech Holdings (02228) announced a placement agreement to issue up to approximately 286 million shares at a price of HKD 9.28 per share, aiming to raise approximately HKD 2.63 billion for various strategic initiatives [1] Group 1: Fundraising Purpose - The net proceeds from the share placement are intended for continuous product iteration and upgrading, enhancing research and development capabilities, and solution capabilities [1] - The funds will also support product commercialization and business development, strengthening collaborations with external parties and partners in similar and mutually beneficial industries [1] - Additional uses of the funds include potential acquisitions and investments, talent attraction and recruitment, working capital replenishment, and general corporate purposes [1]

Core Viewpoint - The company, Guo'en Holdings (08121), has announced a placement agreement to issue up to 5 million shares at a price of HKD 0.60 per share, representing an approximate discount of 11.76% from the market price on the agreement date [1] Group 1: Placement Details - The placement will be conducted through a placement agent to no fewer than six independent third-party subscribers [1] - The estimated net proceeds from the placement are approximately HKD 2.7 million [1] Group 2: Use of Proceeds - The company intends to use the net proceeds entirely to support the development of its healthcare business, which includes hiring suitable talent, covering daily expenses of Shandong Guo'en, launching marketing activities, and developing sales platforms [1]